UY35223A - Moduladores heterocíclicos de receptores de hormonas nucleares - Google Patents

Moduladores heterocíclicos de receptores de hormonas nucleares

Info

Publication number
UY35223A
UY35223A UY0001035223A UY35223A UY35223A UY 35223 A UY35223 A UY 35223A UY 0001035223 A UY0001035223 A UY 0001035223A UY 35223 A UY35223 A UY 35223A UY 35223 A UY35223 A UY 35223A
Authority
UY
Uruguay
Prior art keywords
hormone receptors
nuclear hormone
heterocyclic modulators
modulators
heterocyclic
Prior art date
Application number
UY0001035223A
Other languages
English (en)
Inventor
Friedman Michael
Thomas D Gordon
David C Ihle
Martin E Hayes
Li Bin
Michael Z Hoemann
Somal Gagandeep
Cusack Kevin
Wouter Iwema Bakker
Gloria Y Lo Schiavo
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY35223A publication Critical patent/UY35223A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un compuesto de fórmula (I), sales, prodrogas, metabolitos biológicamente activos, estereoisómeros e isómeros farmacéuticamente aceptables del mismo, en donde las variables se definieron en la presente. Los compuestos de la invención son de utilidad para el tratamiento de condiciones inmunológicas y oncológicas.
UY0001035223A 2012-12-21 2013-12-20 Moduladores heterocíclicos de receptores de hormonas nucleares UY35223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740931P 2012-12-21 2012-12-21
PCT/CN2013/001505 WO2014094357A1 (en) 2012-12-21 2013-12-05 Heterocyclic nuclear hormone receptor modulators

Publications (1)

Publication Number Publication Date
UY35223A true UY35223A (es) 2014-07-31

Family

ID=50977589

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035223A UY35223A (es) 2012-12-21 2013-12-20 Moduladores heterocíclicos de receptores de hormonas nucleares

Country Status (6)

Country Link
US (1) US9150592B2 (es)
EP (1) EP2935284A4 (es)
AR (1) AR094232A1 (es)
TW (1) TW201429959A (es)
UY (1) UY35223A (es)
WO (1) WO2014094357A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
US20200325140A1 (en) * 2016-05-25 2020-10-15 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
ES2971457T3 (es) * 2017-08-23 2024-06-05 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de BCL-2
CN115212312A (zh) * 2022-06-20 2022-10-21 广州惠善医疗技术有限公司 间充质干细胞或其细胞萃取物联合免疫调节剂在制备预防或治疗卵巢早衰药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA927388A (en) * 1970-02-17 1973-05-29 Nakanishi Michio Thieno (2,3-e)(1,4)diazepin-2-ones
DE2040510C3 (de) * 1970-08-14 1980-03-06 Dr. Karl Thomae Gmbh, 7950 Biberach Oxazole- und Thiazole eckige Klammer auf 5,4-d] azepin- Derivate
US3891630A (en) * 1974-03-04 1975-06-24 Abbott Lab Substituted pyrazolo{8 3,4-e{9 {8 1,4{9 thiazepines and isoxazolo{8 5,4-e{9 {8 1,4{9 thiazepines
CA2111138A1 (en) 1993-01-15 1994-07-16 Thierry Godel Octahydrophenanthrene derivatives
AU684874B2 (en) 1993-12-28 1998-01-08 Pharmacia & Upjohn Company Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE69940484D1 (de) 1998-04-06 2009-04-09 Astellas Pharma Inc Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie
DE69922676T2 (de) 1998-10-07 2005-12-15 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
BR0010138B1 (pt) 1999-04-30 2012-12-11 moduladores de receptores de glicocorticóides.
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
EP1325006A2 (en) 2000-08-07 2003-07-09 Neurogen Corporation Heterocyclic compounds as ligands of the gaba a? receptor
IL146057A (en) 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
EP1201649B1 (en) 2000-10-28 2006-05-31 Pfizer Products Inc. Glucocorticoid receptor modulators
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
EP1453832B1 (en) * 2001-12-04 2006-08-09 F. Hoffmann-La Roche AG Ring fused pyrazole derivatives
AU2003221706B2 (en) 2002-04-11 2008-02-28 Merck Sharp & Dohme Corp. 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
US20030224349A1 (en) 2002-05-31 2003-12-04 Pfizer Inc. Rapid assay to assess the potential for glucocorticoid analogs to promote the differentiation of human osteoblasts and predict bone safety
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
JP4503436B2 (ja) 2002-07-08 2010-07-14 ファイザー・プロダクツ・インク 糖質コルチコイド受容体のモジュレーター
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
BRPI0406883A (pt) * 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
EP1599201B1 (en) 2003-02-25 2010-04-14 Merck Sharp & Dohme Corp. Selective non-steroidal glucocorticoid receptor modulators
JP2007511501A (ja) 2003-11-13 2007-05-10 ファイザー・プロダクツ・インク グルココルチコイド受容体調節剤として有用なオクタヒドロフェナンスレンヒドラジド誘導体
CN101060838B (zh) 2004-09-20 2012-02-29 詹森药业有限公司 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物
US20060247266A1 (en) 2004-11-26 2006-11-02 Asahi Kasei Pharma Corporation Nitrogen-containing tricyclic compounds
WO2006081659A1 (en) 2005-02-01 2006-08-10 The University Of British Columbia Meroterpenoid inhibitors of phosphoinositide 3 kinase (pi3k)
ES2414479T3 (es) 2005-04-14 2013-07-19 Glaxo Group Limited Indazoles como ligandos del receptor de glucocorticoides
WO2007044565A2 (en) * 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
GB0522880D0 (en) * 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
JP4873614B2 (ja) 2006-01-16 2012-02-08 国立大学法人 東京大学 カリウムチャネル開口薬
EP2094692B1 (en) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
MY153057A (en) 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
PL2114888T3 (pl) 2007-02-02 2011-04-29 Pfizer Prod Inc Związki trójcykliczne i ich zastosowanie jako modulatorów receptora glukokortykoidowego
CN101878221B (zh) 2007-11-30 2014-04-02 辉瑞有限公司 糖皮质激素受体激动剂
JP2009209068A (ja) 2008-03-03 2009-09-17 Univ Of Tokyo カリウムチャネル開口薬
WO2009149139A1 (en) * 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
NZ590559A (en) 2008-07-28 2011-09-30 Pfizer Phenanthrenone compounds, compositions and methods
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
WO2010136940A1 (en) 2009-05-29 2010-12-02 Pfizer Limited Novel glucocorticoid receptor agonists
WO2011081173A1 (ja) 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
CN102584860B (zh) * 2011-01-17 2014-12-10 苏州大学 含吲哚结构的螺杂环化合物及其制备方法
CA2830234A1 (en) 2011-03-15 2012-09-20 Abbvie Inc. Nuclear hormone receptor modulators
JP6096778B2 (ja) * 2011-09-01 2017-03-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピロロピラジンキナーゼ阻害剤
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑

Also Published As

Publication number Publication date
EP2935284A4 (en) 2016-04-27
TW201429959A (zh) 2014-08-01
EP2935284A1 (en) 2015-10-28
US20140179676A1 (en) 2014-06-26
US9150592B2 (en) 2015-10-06
WO2014094357A1 (en) 2014-06-26
AR094232A1 (es) 2015-07-22

Similar Documents

Publication Publication Date Title
CR20130500A (es) Moduladores de los receptores de hormonas nucleares
UY35630A (es) Carboxamidas primarias como inhibidores de btk
CR20160007A (es) Nuevos compuestos triciclicos
CO6561771A2 (es) Nuevos compuestos triciclicos
ECSP12011968A (es) Nuevos compuestos tricíclicos
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
UY36629A (es) Indazolonas como moduladores de la señalización de tnf
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY36630A (es) Moduladores tricíclicos de la señalización por tnf
ECSP15025947A (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
CU20130139A7 (es) Derivados glocósidos y usos de los mismos
ECSP13013026A (es) Isoxazolinas como agentes terapéuticos
CO2017012594A2 (es) Moduladores de receptor nuclear
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
UY36628A (es) Indazolonas como moduladores de la señalización de tnf
UY35223A (es) Moduladores heterocíclicos de receptores de hormonas nucleares
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
UY35014A (es) Moduladores heterocíclicos de los receptores de hormonas nucleares
CU20140127A7 (es) Moduladores de la ruta del complemento y usos de los mismos
CO7141426A2 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20150714